Published in Medical Patent Business Week, November 16th, 2007
Semapimod is a synthetic guanylhydrazone that inhibits the activity of various kinases, including Raf kinase, a key enzyme in the MAPK/ERK signal transduction pathway. Semapimod's inhibition of Raf-kinase...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Business Week